HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Depression in oncologists: For many, a closely guarded secret
• Should psychotherapy be mandatory for medical students/residents?
• Slow progress in advanced mesothelioma: Is the FDA winning the battle with the EPA? Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
• Antineoplastic therapy ordering protocol allows APPs to ‘expand their scope of practice’ Archana Ajmera, MSN, ANP-BC, AOCNP
• Trained dogs ‘sniff out cancer in blood’ with high accuracy
• Novel KRAS inhibitor induces disease control in 96% of treated patients with non-small cell lung cancer
• Front-line osimertinib improves OS in EGFR-mutated lung cancer
• Abemaciclib plus fulvestrant extends OS in endocrine therapy-refractory advanced breast cancer
• Niraparib significantly extends PFS in newly diagnosed advanced ovarian cancer
• HCC trial misses OS endpoint, but researchers report ‘clinically meaningful’ benefit with nivolumab
• Addition of docetaxel to androgren deprivation confers durable OS benefit for metastatic prostate cancer
• Comprehensive cancer center second opinions benefit black patients with breast cancer
• ‘Urgent need’ exists to better educate LGBTQI+ Latinx individuals on cancer screening, prevention
• High-dose radiation effective in oligometastatic prostate cancer
• Durvalumab reduces local, distant progression in non-small cell lung cancer
• Breast cancer survivors who smoke, use hormones face higher lung cancer risk
• Neoadjuvant chemoimmunotherapy induces high rate of pathologic response in lung cancer subset
• Atezolizumab plus chemotherapy extends survival in PD-L1-high advanced NSCLC
• Risk prediction model outperforms US screening criteria for lung cancer detection
• Specialist nurses add efficiency, continuity to follow-up after lung cancer resection
• Selpercatinib induces deep, durable responses in RET fusion-positive lung cancer
• Nurse-led virtual lung cancer clinic transforms patient, staff experience
• Three-year survival update confirms efficacy of pembrolizumab in non-small cell lung cancer
• Nivolumab confers fivefold OS improvement over chemotherapy in advanced NSCLC
• ASTRO honors three Gold Medal recipients
• UCLA professor honored for contributions to lung cancer prevention
• Nivolumab regimen ‘highly active’ in relapsed/refractory primary mediastinal large B-cell lymphoma
• Familial risks identified across hematologic malignancies
• USPSTF recommends preventive drugs for women at high breast cancer risk
• Low-dose rituximab induces high response rates in acquired thrombotic thrombocytopenic purpura
• De-intensified chemoradiotherapy confers favorable outcomes in HPV-associated oropharyngeal cancer
• Top-ranked cancer hospitals outperform affiliates in surgical safety, mortality risk
• FDA approves Rozlytrek for cancers with NTRK gene fusion, ROS1-positive non-small cell lung cancer
• FDA approves Inrebic for myelofibrosis
• At FDA’s request, Allergan recalls breast implants linked to rare lymphoma
• FDA grants orphan drug designation to SIG-001 for hemophilia A
• Two cancer centers earn NCI designation